Biological optimization for treatment planning in carbon ion therapy is currently based on the first version of the local effect model (LEM I). Further developments implemented in the latest version (LEM IV) allowed to predict more accurately the Relative Biological Effectiveness (RBE) in-vitro. The main goal of this study is to compare the LEM IV against LEM I under treatment-like conditions for idealized target geometries. Therefore, physical dose distributions resulting from the biological optimization with LEM I were used to recalculate the RBE-weighted dose distribution based on LEM IV. Input parameters representing the clinical endpoints late toxicity in the central nervous system and the tumor control for chordoma were chosen to investigate the impact of changes on the predicted isoeffective dose levels. The recalculated RBE-weighted dose distributions show an increase within the target region, and the mean RBE-weighted dose values are dependent on the geometry and decrease with increasing target dimension. The differences between predictions of LEM IV and LEM I are less than 10% for typical tumor volumes treated in the pilot project at GSI. Median RBE-weighted doses predicted by LEM IV in the target region are consistent with clinically observed dose-response behavior as demonstrated by comparison to the 5-year local control curve for skull base chordoma. 7 Present address:
Introduction
Ion beam therapy requires accurate predictions of the relative biological effectiveness (RBE). For treatment planning the clinical relevant RBE of ions in cells and tissue has to be considered to obtain a homogeneous RBE-weighted dose within the target volume. In order to achieve that goal, different strategies have been developed at Heavy Ion Medical Accelerator Japan (HIMAC) and for the pilot project performed at the GSI Helmholtz Centre for Heavy Ion Research (GSI). At HIMAC, an approach based on experimental in-vitro data in combination with the clinical experience obtained with neutron beams has been implemented (Kanai et al 1997 (Kanai et al , 1999 . More recently, this approach has been extended by including biophysical modeling to adapt the treatment planning to treatments using scanned beams (Kase et al 2006 , Inaniwa et al 2010 .
For the GSI pilot project, the RBE of carbon ions was predicted by the Local Effect Model (LEM I) in conjunction with the treatment planning software TRiP98 (Treatment Planning for Particles, 98 edition) (Scholz et al 1997 , Krämer et al 2000 , Schardt et al 2010 . The LEM can predict the biological effect of ions from the response of cells and tissues to photon radiation. The analysis of the dose-response curves for local control of skull base chordoma and normal tissue reactions observed in the pilot project suggest that the clinical results can be expressed sufficiently accurate by the RBE predictions of the LEM I (Schulz-Ertner et al 2007, Schlampp et al 2011) . Experimental data, however, showed an overestimation of the RBE-weighted dose for light ions in general and for carbon ions in the entrance channel (Karger et al 2006 . These differences were not crucial for treatment safety, since the actual RBE-weighted dose in the entrance channel was less than predicted by the model. Nevertheless, a better agreement with the experimental data is important for the general applicability of the model in treatment planning, particularly also for other entities like the RBE-weighted dose in the healthy tissue as well as systematic comparisons between different tumor types and ion species.
Consequently, the LEM has been constantly improved with respect to biological parameters and mechanisms. The LEM I (Scholz et al 1997) directly links the local dose deposition pattern in the cell nuclei to the dose-response curve of photons. LEM II (Elsässer and Scholz 2007) and LEM III keep on pursuing this approach. In the recent version (LEM IV, Elsässer et al 2010 an intermediate step is introduced: rather than the local dose, the complexity of the radiation damage in terms of microscopic double-strand break distribution on the DNA is considered . This damage distribution pattern is assumed to better represent the processes leading to the finally observed biological effect, and consequently should lead to a better prediction of the RBE.
However, despite the changes in the model, predictions of the RBE-weighted dose for the target regions should not be significantly affected to be consistent with the clinical results obtained so far, since these have been demonstrated to be in agreement already with the LEM I (Schulz-Ertner et al 2007, Schlampp et al 2011) . The latest version of the model (LEM IV) has already demonstrated a better description of in-vitro data but has not yet been compared in detail with clinical results. Hence, the agreement of the RBE predictions based on LEM IV with those of LEM I as well as with clinical data is investigated. For the comparison with the clinical outcome for the treatment of chordoma of the skull base with carbon ions in the GSI pilot project (Schulz-Ertner et al 2007) the clinical endpoints late toxicity in the central nervous system (CNS) evaluated in the rat spinal cord experiment (Karger et al 2006) and local control of chordoma evaluated from clinical studies of hypofractionated photon radiotherapy (Henderson et al 2009) were considered for the RBE prediction. Idealized target volumes instead of real patient plans were used to point out the major differences between LEM I and LEM IV. In patient plans other aspects like field configuration, target geometries, margins and inter-patient heterogeneity could smear out the difference between LEM I and LEM IV and make a systematic analysis difficult. Therefore this study concentrates on a systematic analysis with idealized geometries rather than real patient plans which can be transferred to the clinical situation in a further step. A detailed analysis of the individual patient plans as well as the comparison of the LEM to other models of the literature will follow in a separate publication.
Materials and methods

Treatment planning
To compare the predictions of LEM IV against LEM I under treatment-like conditions, idealized target geometries (spheres and cubes) were used to facilitate the systematic comparison of the different LEM versions. The cubic volume has a fixed lateral dimension of 50 × 50 mm but varies in its dimension along the beam axis. For the spherical volume, the diameter varies between 20 to 100 mm (20 mm steps) and the target point along the beam axis (center of volume) varied from 50 to 200 mm depth (50 mm steps). These target configurations cover the whole spectrum of clinically relevant situations. Treatment plans consisted of two directly opposing fields in line with the majority of field arrangements in the pilot project. The treatment planning system TRiP98 was used to optimize the physical dose distribution with the RBE predictions based on LEM I to achieve a homogeneous RBE-weighted depth dose profile (Krämer et al 2000) .
For comparison with the previously published dose-response curve for chordoma of the skull base treated in the GSI clinical trial (Schulz-Ertner et al 2007 , Schulz-Ertner et al 2002 , the median (80.3 ml), minimum (13.9 ml) and maximum (594.2 ml) tumor volumes representing the patient population were considered. For the analysis, volumes close to the original ones expressed with spheres of 53.5, 29.8 and 104.3 mm diameter respectively were used. These volumes refer to the subvolume (PTV2) of the initial planning target volume (PTV1) to account for the macroscopic tumor as well as a safety margin for localization uncertainty. For this analysis, PTV2 was assumed to cover 65% of PTV1, which was a representative value for the patient population regarded. Treatments were performed with 15 fractions to PTV1 and 5 fractions to PTV2. The RBE-weighted dose per fraction was chosen as 3 Gy (RBE) and 3.5 Gy (RBE), corresponding to the clinically applied values (Schulz-Ertner et al 2002) .
RBE data
For clinical application, the LEM is used to calculate energy dependent RBE values for all projectiles from protons to neon which are stored in a so-called 'RBE-table' and used as input for the TRiP98 treatment planning program.
As the LEM derives the biological effect of ions from the dose-response to photon radiation, the biological input parameters of the LEM are the parameters α γ , β γ and D t characterizing the photon dose-response curves according to the linear-quadratic model (LQ model) and extended by the threshold dose D t (Astrahan 2008) describing the transition into a purely exponential shape (Elsässer and Scholz 2007) . The transition dose D t is necessary because the dose-response curve is needed up to very high doses since the LEM uses instead of a macroscopic dose scale rather the local dose deposition within individual particle traversals. Thus the threshold dose D t has to be considered even for small fraction sizes, i.e. 3-4 Gy (RBE), to describe the photon-dose response up to high photon doses potentially needed. For the analysis three different RBE tables were used (table 1) characterized by their α γ , β γ and D t value. All other parameters of the LEM are kept constant and chosen as described in Elsässer et al (2010) . RBE table AB2 I was used during the clinical trial at GSI. The α γ /β γ -ratio of 2 Gy was selected as it is characteristic for late toxicity in the CNS (Karger et al 2006) . Since no data were available for photon α γ /β γ -ratios of chordoma tumors at the beginning of the pilot project, the particular choice of α γ /β γ = 2 Gy also for chordomas has been based on more general considerations concerning a potential correlation between the α γ /β γ -ratio and tumor volume doubling times, as suggested e.g. by the clinical data reported by Battermann et al (1981) .
The RBE table AB2 IV calculated with the LEM IV is based on the same biological endpoint, i.e. the same α γ /β γ -ratio of 2 Gy, but the biological input parameters α γ , β γ as well as D t were updated. Lower absolute values of α γ and β γ were chosen in accordance with recent findings concerning the observed difference of the absolute LQ-parameters between in-vitro and in-vivo endpoints independent on the tumor type (endpoint), i.e. the α γ /β γ -ratio (Tai et al 2008 , Henderson et al 2009 .
Recently, also LQ-parameters for tumor control of chordoma became available from clinical studies of hypofractionated photon radiotherapy (Henderson et al 2009) ; as we focus on the analysis of the clinical results for chordoma of the skull base these are used for the third RBE table AB2.45 IV, also calculated with the LEM IV. Here, D t is increased in line with an analysis of cell survival data suggesting an increase of D t with increasing photon α γ /β γ -ratio .
Evaluation of the treatment plans
The impact of the model enhancement was investigated based on a reference physical depth dose profile obtained from a biological optimization using the LEM I (AB2 I). The resulting physical depth dose profile is used as input for a recalculation of the RBE-weighted dose based on the new model (AB2 IV and AB2.45 IV). Thus, the physical dose distributions were identical for both profiles and differences in the RBE-weighted dose can be uniquely attributed to the change of the LEM version. We focus here on the analysis of the target volume because clinical data are available, in contrast to the entrance channel where the clinical data are not yet available. Considering the dose volume histogram (DVH), the median and mean RBE-weighted doses were regarded for statistical comparison.
Local control
To assess the impact of the model enhancement, the dose-response data for 5-year local control of chordoma as compiled by Schulz-Ertner et al (2007) were reanalyzed by (i) replacing the clinical target geometries by the idealized PTV1 and PTV2, and (ii) by recalculating the LEM I-optimized dose distributions with LEM IV using the RBE tables described in table 1.
As the recalculated RBE-weighted dose distributions are inhomogeneous, the equivalent uniform dose (EUD) can be used to further characterize the RBE-weighted dose distribution. If in the case of tumor tissue the corresponding linear-quadratic parameters describe the cell survival, the EUD can be determined from the mean or median survival S in the target volume by
where α γ and β γ are the photon parameters of the LQ model (Niemierko 1997) . Due to the nonlinearity of the dose-response curve, dose fluctuations can have an increased impact on cell survival. This is related to the linear-quadratic dependence of the dose-response curve. Strong deviations from the planned target dose can therefore lead to a disproportionately higher or lower survival rate becoming perceivable in the EUD. Also the median RBE-weighted dose was considered as representative, since it reflects the EUD of the tumor in case of directly opposing fields (Steinsträter et al 2012) .
For comparison with the dose response curve given in Schulz-Ertner et al 2007, the obtained median RBE-weighted doses were recalculated to isoeffective doses using a fractionation schedule of 2 Gy (RBE) per fraction (d ref ) according to Wambersie et al (2006) :
where d and D are the actually applied fractional and total RBE-weighted doses, respectively. For the determination of the EUD and the isoeffective dose an α γ /β γ -ratio describing the endpoint under consideration is needed; therefore the α γ /β γ -ratios associated with the RBE tables described in table 1 were used.
Results
Dose analysis of idealized geometries
Using the RBE table AB2 IV for the RBE prediction results in an increase of the RBEweighted dose towards the distal end of the target volume as illustrated in figure 1(a) . This increase can be explained by the more detailed consideration of correlated double strand breaks (DSB) within small subvolumes thus leading to a stronger variation of RBE with LET and consequently a steeper gradient of RBE with depth compared to the LEM I. Moreover it is shown that the shapes of the distal parts of the RBE-weighted depth dose profiles are the same for all investigated target dimensions. This is due to the fact that the composition of the distal part of the SOBP is not affected by adding Bragg peaks at the proximal part when increasing the dimension of the SOBP, apart from an obviously minor contribution of lighter fragments. When two opposing fields are used, as typically applied in the GSI clinical trial, the gradient of the RBE-weighted dose throughout the target region is substantially diminished, ( figure 1(b) ). The degree of RBE homogenization decreases with increasing target dimension. The configuration with opposing fields leads to the largest LET-homogenization compared to other field configurations like for example a single field or (right) angled fields. Thus for the opposing fields also the largest RBE gradient compensation is observed. For nonopposing field configurations, i.e. angled fields, a less pronounced compensation is expected. For different depth localizations, only minor differences in the shape of the RBE-weighted depth-dose profiles are observed (data not shown). In table 2 RBE-values for the RBE-tables described in table 1 for an SOBP of 60 mm dimension from 75 to 125 mm depth as shown in figure 1(a) are tabulated to provide detailed information of the RBE for different dose-levels. In figure 2 , the corresponding mean RBE-weighted doses are plotted as a function of the target dimension. For RBE predictions with AB2 IV, the mean RBE-weighted dose decreases with increasing dimension. This can be explained by the underestimation of the RBE-weighted dose as compared to LEM I in the center of the target volume which is increasingly composed of dose contributions with photon like efficiency leading to a decreased RBE and thus leading to an overall decrease in the mean RBE-weighted dose. Consequently, the RBE-weighted dose variation as expressed by the standard deviation increases with increasing dimension (3-7%). As suggested before, the shape of the target volume has an impact on the RBE-weighted dose too. For the spherical volumes a higher RBE-weighted dose is observed as compared to the cubic volumes for a given dimension. Besides the mean RBE-weighted dose also the median is calculated and shows no significant deviation (<3%) from the mean (data not shown).
Apart from the agreement of mean or median RBE-weighted doses as described above, it is of interest to assess the potential impact of the heterogeneity of the RBE-weighted dose distribution in individual fields. Hence, also the equivalent uniform dose (EUD) calculated from the mean cell survival was analyzed (Niemierko 1997) . The EUD shows only slight deviations from the mean and median RBE-weighted dose (figure 2). This suggests that the heterogeneity of the RBE-weighted dose distribution has no particular impact in terms of disproportional higher or lower overall effect resulting from an over-or underestimation of the RBE-weighted dose distribution at the distal and proximal end of the target volume, respectively. 
Local control analysis
Comparison of local control rates with other treatment modalities like e.g. modern photon techniques or proton treatments requires the accurate estimation of RBE values. For the clinical evaluation of the LEM IV the consistency of the predicted RBE-weighted dose with the dose-response curve for local control of skull base chordoma as reported by Schulz-Ertner et al (2007) is important. For this purpose the isoeffective dose for the reference fractionation schedule of 2 Gy per fraction was chosen to compare different studies in the literature (SchulzErtner et al 2007) .
A RBE-weighted target dose of 60 Gy (RBE) in 15+5 fractions of 3 Gy (RBE) and the linear quadratic parameters corresponding to the RBE table A2 I lead to an isoeffective dose of 75 Gy (IsoE) for a fraction size of 2 Gy in PTV2. The corresponding tumor control probability of 63% has shown to be in good agreement with the results obtained in studies using photon and proton treatments, thus indicating that the estimation of RBE based on LEM I was sufficiently accurate.
When analyzing the impact of the transition to LEM IV, the dependence on the target dimensions as illustrated in figure 2 has to be taken into account. Recalculations of the median isoeffective dose based on the RBE tables AB2 IV and AB2.45 IV were thus performed for idealized PTV1 and PTV2 (spheres). Figure 3 illustrates the physical and RBE-weighted dose distributions as applied in 15 + 5 fractions leading to 60 Gy (RBE) in the idealized PTV2 of 78.3 ml, representing the median value of the patient population (Schulz-Ertner et al 2007) .
Furthermore, the local control rates of the original clinical collective (Schulz-Ertner et al 2007) are plotted against the median isoeffective doses predicted here for the idealized PTV2. These response data points are then compared with the mentioned dose response curve for local control of chordoma (figure 4), which also includes the original response data points from the GSI pilot project (LEM I based doses). Note that the median isoeffective doses attributed to the local control rates within the other studies refer to the median dose applied in the patient population whereas the recalculated doses refer to the median isoeffective dose within the above-described idealized PTV2. (2007) with reanalyzed data points referring to the median isoeffective dose achieved with (a) the RBE table AB2 IV and (b) AB2.45 IV for a idealized PTV2 of 78.3 ml and corresponding PTV1 as well as for a PTV2 of 13.6 ml and 578.9 ml to show the dependence of the isoeffective dose on the target volume dimension.
Sensitivity
To assess the uncertainties of the photon input data, the sensitivity on variations of α γ , β γ and D t was analyzed (table 3). The RBE-weighted dose was therefore optimized to 3 Gy (RBE) with the corresponding reference RBE-table.
Changing the parameters by 25% results in variations of the RBE-weighted dose by less than 10%, which is in the order of the scatter of the clinical data around the adjusted TCP curve in figure 4 . This is thus considered to be sufficiently robust for clinical application.
Discussion
To fully exploit the potential advantages of ion beams for therapy requires to prospectively estimate the RBE as accurately as possible for treatment planning. Biophysical models represent a powerful tool to achieve this goal and have been demonstrated to allow RBE predictions with reasonable accuracy for different endpoints in-vitro (Elsässer and Scholz 2007, Inaniwa et al 2010) , in-vivo (Karger et al 2006 , Debus et al 2003 and for clinical applications (Schulz-Ertner et al 2007 , Schlampp et al 2011 . Nevertheless, the first version of LEM I implemented in the treatment planning for the GSI pilot project has been shown to have certain limitations with respect to the accuracy of the RBE predictions in the entrance region and for lighter particles like e.g. protons. Subsequent enhancements of the LEM have been demonstrated to substantially improve the accuracy of the model in biological experiments (Elsässer and Scholz 2007 .
In agreement with experimental data the latest version, LEM IV, predicts a more pronounced increase of RBE with LET as compared to the LEM I. This leads to the inhomogeneity and the rise of the RBE-weighted dose towards the distal end of the target volume, when the RBE-weighted dose is obtained from the physical dose resulting from the optimization based on LEM I.
In order to estimate the clinical impact of this more pronounced RBE gradient it is important to assess the accuracy of the model predictions for clinically relevant endpoints, e.g. late effects in the CNS. Experiments analyzing the tolerance of the rat spinal cord according to Karger et al (2006) revealed that the RBE predicted with the LEM I was underestimated by about 25% in the Bragg-peak region. Using instead the LEMIV-based RBE table AB2 IV with LQ-parameters describing the dose response behavior in the experiment of Karger et al (2006) results in a higher RBE which is in much better agreement with the measured values (figure 5). In line with the in vitro data presented in Elsässer et al (2010) , this further demonstrates the improvement of the LEM IV as compared to the LEM I also for in vivo data.
Consequently, the question arises whether this steeper gradient of the RBE and the resulting inhomogeneity of the RBE-weighted dose distribution would be clinically significant when reanalyzing the clinical results obtained in the clinical trial with carbon ions at GSI.
Here it is important to note that large parts of the inhomogeneity are already compensated when using two opposing fields, representing the typical situation for the chordoma patients treated at GSI. The remaining inhomogeneity and the corresponding difference of the mean RBE-weighted dose as compared to the LEM I prediction primarily depend on the shape and dimension of the target volume.
For typical tumor volumes as treated within the pilot project, the mean values of the RBE-weighted dose according to LEM IV are very similar compared to those of LEM I (a) (b) Figure 5 . RBE distribution predicted with (a) the RBE table AB2I and (b) the RBE table AB2 IV for the irradiation of the spinal cord in rats according to Karger et al (2006) compared to the measured RBE (position uncertainty: ± 2 mm within SOBP). Note that the scales in (a) and (b) differ.
(table 2, figure 2). When taking into account the distribution of tumor volumes for a typical patient population, the smaller volumes would get a larger RBE-weighted dose, whereas for the larger volumes a lower RBE-weighted dose would be expected. This could have an impact on the local control probability of individual patients. In a population-based clinical analysis, however, this larger spread would probably not be detectable within the other uncertainties like e.g. inter-patient heterogeneity of radiation sensitivity, and thus the agreement in the mean values is most important here.
The reanalysis of the isoeffective dose clearly indicates that the transition from LEM I to LEM IV would have no significant impact on the TCP dose-response curve. Since the LQparameters α γ and β γ published in Henderson et al (2009) are very low and also the absolute values published in Tai et al (2008) for liver cancer are lower than comparable in-vitro data we concluded a trend towards lower absolute values for in-vivo endpoints compared to in-vitro.
We demonstrated with this study that the dose-response behavior in terms of local control for chordoma and late effects in the CNS can be well described with lower absolute values independent on the α γ /β γ -ratio. Therefore, the RBE values predicted with LEM IV and the RBE tables AB2 IV as well as the AB2.45 IV with updated parameters are consistent with the available clinical data for local control of chordoma (Schulz-Ertner et al 2007) .
Besides comparison of the different LEM model versions, comparison to other models potentially applicable in treatment planning, as e.g. the MKM (Inaniwa et al 2010) or RMF (Carlson et al 2008 , Frese et al 2012 would be of interest. However, at present a direct comparison of models on the basis of published results is mainly hindered by the fact that the different biological models are used in combination with different physical models that are required to characterize the radiation field. For example, Frese et al (2012) use the RFM in combination with a simple physics model that completely neglects nuclear interactions and beam fragmentation. Inaniwa et al (2010) use the MKM in combination with a more realistic physics model based on Geant4, which might however differ from the approach implemented in TRiP98. As a consequence, differences in RBE predictions cannot be uniquely attributed to the different biological models, but might also arise from the differences in the underlying physics description. We are thus currently implementing an interface to the TRiP98 environment that will allow to use any biological model that is capable of predicting dose response curves as a function of the particle species and energy or LET. With that, the different models can be compared on the basis of exactly the same physical composition of the radiation field.
The analysis presented here is based on idealized volumes (spheres and cubes) and focuses on a general understanding of the main trends. It remains to be elucidated in how far the conclusions from these idealized geometries can be transferred to the situation of real patient treatment plans. Therefore, LEM IV based recalculations of patient treatment plans are currently performed (Gillmann 2011) . Similarly, the impact of the model enhancement on the analysis of normal tissue complications as reported by Schlampp et al (2011) will be assessed.
As a consequence of the differences between LEM I and LEM IV, biological optimization in treatment planning based on LEM IV would lead to an increase of the physical dose in the center of the target volume and a reduction of the physical dose at the border as compared to an optimization with LEM I. Implementation of the LEM IV and the replacement of LEM I in treatment planning thus requires a thorough clinical assessment of the balance between the potentially higher effect in the center and reduction of the effect at the field boarders.
Conclusion
The differences in the prediction of RBE-weighted doses and isoeffective doses between LEM I and LEM IV for typical tumor volumes, i.e. averaged over the patient population in the GSI pilot project, are less than 10%. Thus, based on the analysis of idealized target geometries, the transition to LEM IV is not expected to lead to significant differences of the TCP dose-response relationship for chordoma as compared to the analysis based on LEM I.
